| 1 |
Formulation development and pharmacokinetic evaluation of enteric-coated dexrabeprazole tablets |
|
|
| Tae Jin Lee, Dohyun Kim, Jae Cheon Kim, Si Won Ro, Dong Hee Na |
|
| Journal of Pharmaceutical Investigation. 2022; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 2 |
GASTROPROTECTIVE AND ULCER HEALING ACTIVITY OF ETHANOLIC EXTRACT OF ADIANTUM LUNULATUM |
|
|
| M. N Deshpande, N Balekar |
|
| INDIAN DRUGS. 2019; 56(03): 68 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 3 |
Development and Validation of Rapid, Sensitive Rp-Uplc Method for Determination of Related Impurities in Dexrabeprazole Sodium |
|
|
| Santosh T. Khadangale, Vitthal M. Dhalape, Rahul V. Pinjari |
|
| Oriental Journal of Chemistry. 2018; 34(5): 2425 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 4 |
Antioxidant and anti-inflammatory activities contribute to the prophylactic effect of semi-purified fractions obtained from the crude methanol extract of Muntingia calabura leaves against gastric ulceration in rats |
|
|
| Tavamani Balan,Mohd. Hijaz Mohd Sani,Salahuddin Haji Mumtaz Ahmad,Velan Suppaiah,Norhafizah Mohtarrudin,Zainul Amiruddin Zakaria |
|
| Journal of Ethnopharmacology. 2015; 164: 1 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 5 |
Normal and polar-organic-phase high-performance liquid chromatographic enantioresolution of omeprazole, rabeprazole, lansoprazole and pantoprazole using monochloro-methylated cellulose-based chiral stationary phase and determination of dexrabeprazole |
|
|
| Shuchi Dixit,Rituraj Dubey,Ravi Bhushan |
|
| Biomedical Chromatography. 2013; : n/a |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 6 |
The chiral bioconversion and preclinical pharmacokinetic analysis of (R)-(+)-rabeprazole in beagle dogs by HPLC and HPLC-MS/MS |
|
|
| Yan-hui Gao,Jia-xing Xu,Zhong-xue Su,Li Song,Hong-xiang Lou |
|
| Biomedical Chromatography. 2013; 27(11): 1380 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 7 |
Antiulcer activity ofMuntingia calaburaleaves involves the modulation of endogenous nitric oxide and nonprotein sulfhydryl compounds |
|
|
| Tavamani Balan,Mohd. Hijaz Mohd. Sani,Velan Suppaiah,Norhafizah Mohtarrudin,Zarizal Suhaili,Zuraini Ahmad,Zainul Amiruddin Zakaria |
|
| Pharmaceutical Biology. 2013; : 1 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 8 |
Stability-indicating TLC-densitometric method for estimation of dexrabeprazole and domperidone in pharmaceutical dosage form |
|
|
| Chitlange, S.S., Mulla, A.I., Pawbake, G.R., Wankhede, S.B. |
|
| Preparative Biochemistry and Biotechnology. 2010; 40(4): 337-346 |
|
| [Pubmed] [Google Scholar] |
|
| 9 |
A postmarketing surveillance study of dexrabeprazole in the treatment of acid peptic disorders |
|
|
| Jain, S.C. |
|
| Journal of the Indian Medical Association. 2009; 107(2): 111-113 |
|
| [Pubmed] [Google Scholar] |
|
| 10 |
Is the required therapeutic effect always achieved by racemic switch of proton-pump inhibitors? |
|
|
| Zhou, Q., Yan, X.-F., Pan, W.-S., Zeng, S. |
|
| World Journal of Gastroenterology. 2008; 14(16): 2617-2619 |
|
| [Pubmed] [Google Scholar] |
|
| 11 |
Randomized, double-blind, comparative study of dexrabeprazole 10 mg versus rabeprazole 20 mg in the treatment of gastroesophageal reflux disease |
|
|
| Pai, V., Pai, N. |
|
| World Journal of Gastroenterology. 2007; 13(30): 4100-4102 |
|
| [Pubmed] [Google Scholar] |
|
| 12 |
Recent advances in chirally pure proton pump inhibitors |
|
|
| Pai, V., Pai, N. |
|
| Journal of the Indian Medical Association. 2007; 105(8): 469-474 |
|
| [Pubmed] [Google Scholar] |
|
